{"id":744924,"date":"2014-09-17T08:31:00","date_gmt":"2014-09-17T08:31:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/"},"modified":"2023-03-22T00:04:51","modified_gmt":"2023-03-22T04:04:51","slug":"merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/","title":{"rendered":"Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes"},"content":{"rendered":"<p class=\"bwalignc\">       Omarigliptin significantly reduced HbA1c levels compared to placebo     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of the first data from the Phase 3<br \/>\n      clinical development program for omarigliptin, Merck\u2019s investigational<br \/>\n      once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a<br \/>\n      study in Japanese patients, omarigliptin provided comparable efficacy<br \/>\n      and tolerability to Merck\u2019s once-daily DPP-4 inhibitor JANUVIA<sup>\u00ae<\/sup><br \/>\n      (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin<br \/>\n      in Japan. Merck presented these data on omarigliptin, which has been<br \/>\n      shown to produce sustained DPP-4 inhibition, at an oral session at the 50<sup>th<\/sup><br \/>\n      European Association for the Study of Diabetes (EASD) Annual Meeting.\n    <\/p>\n<p>\n      \u201cDespite advances in diabetes care in recent years, many people living<br \/>\n      with type 2 diabetes are not at recommended blood sugar goals,\u201d said<br \/>\n      Peter Stein, M.D., vice president, Clinical Research, Diabetes and<br \/>\n      Endocrinology, Merck Research Laboratories. \u201cMerck is committed to<br \/>\n      helping patients reduce the complexities of managing diabetes. If<br \/>\n      approved, omarigliptin, as a once-weekly medication, could provide an<br \/>\n      important new treatment option to help patients attain their blood sugar<br \/>\n      goals.\u201d\n    <\/p>\n<p>\n      Merck is supporting omarigliptin with a global clinical development<br \/>\n      program that includes 10 Phase 3 clinical trials involving approximately<br \/>\n      8,000 patients with type 2 diabetes. These are the first Phase 3 data<br \/>\n      presented for omarigliptin and are the pivotal data for filing in Japan.<br \/>\n      As previously announced, Merck plans to file for approval in Japan by<br \/>\n      the end of 2014.\n    <\/p>\n<p>\n      <b>About the study<\/b>\n    <\/p>\n<p>\n      The Phase 3 double-blind, non-inferiority trial assessed the efficacy,<br \/>\n      safety and tolerability of omarigliptin 25 mg once-weekly compared to<br \/>\n      sitagliptin 50 mg once-daily (standard starting dose in Japan), and to<br \/>\n      placebo. The primary efficacy endpoint was the change in HbA1c<sup>1<\/sup><br \/>\n      levels from baseline at week 24.\n    <\/p>\n<p>\n      At baseline, randomized patients (n=414) had a mean HbA1c concentration<br \/>\n      of 7.9, 8.0 and 8.1 percent in the omarigliptin, sitagliptin and placebo<br \/>\n      groups, respectively. Mean fasting plasma glucose (FPG) levels were also<br \/>\n      similar between treatment groups.\n    <\/p>\n<p>\n      The primary objectives of the study were met, demonstrating at 24 weeks<br \/>\n      a significant change from baseline in lowering HbA1c levels versus<br \/>\n      placebo, while demonstrating similar efficacy to sitagliptin.\n    <\/p>\n<p>\n      At week 24, omarigliptin significantly reduced HbA1c levels by -0.80<br \/>\n      percent from baseline relative to placebo. The change relative to<br \/>\n      sitagliptin was -0.02 percent and met the prespecified non-inferiority<br \/>\n      criterion. The pre-specified criterion was based on the upper bound of<br \/>\n      the 95 percent confidence interval (CI) being less than 0.3 percent.<br \/>\n      Fasting and two-hour post-meal blood sugar levels also were<br \/>\n      significantly reduced from baseline with omarigliptin and sitagliptin<br \/>\n      compared to placebo.\n    <\/p>\n<p>\n      There were no meaningful differences in the incidences of adverse events<br \/>\n      with omarigliptin compared to placebo and sitagliptin. The most common<br \/>\n      adverse event that occurred with an incidence of greater than 3 percent<br \/>\n      in the omarigliptin group was nasopharyngitis, which occurred in 12.7<br \/>\n      percent of those treated, compared to 30.5 percent of patients receiving<br \/>\n      placebo and 11.0 percent of those receiving sitagliptin. Symptomatic<br \/>\n      hypoglycemia was uncommon across all treatment groups in this study<br \/>\n      [omarigliptin (0), sitagliptin (1), and placebo (0)]. Omarigliptin was<br \/>\n      generally weight neutral, with a 0.04 kg mean change from baseline at<br \/>\n      week 24.\n    <\/p>\n<p>\n      <b>About JANUVIA<\/b><sup><b>\u00ae<\/b><\/sup><b> (sitagliptin)<\/b>\n    <\/p>\n<p>\n      JANUVIA is indicated, as an adjunct to diet and exercise, to improve<br \/>\n      glycemic control in adults with type 2 diabetes mellitus. JANUVIA should<br \/>\n      not be used in patients with type 1 diabetes or for the treatment of<br \/>\n      diabetic ketoacidosis. JANUVIA has not been studied in patients with a<br \/>\n      history of pancreatitis. It is unknown whether patients with a history<br \/>\n      of pancreatitis are at increased risk of developing pancreatitis while<br \/>\n      taking JANUVIA. JANUVIA is contraindicated in patients with a history of<br \/>\n      a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis<br \/>\n      or angioedema.\n    <\/p>\n<p>\n      <b>Selected important risk information about JANUVIA (sitagliptin) 25<br \/>\n      mg, 50 mg and 100 mg tablets<\/b>\n    <\/p>\n<p>\n      There have been postmarketing reports of acute pancreatitis, including<br \/>\n      fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients<br \/>\n      taking JANUVIA. After initiating JANUVIA, observe patients carefully for<br \/>\n      signs and symptoms of pancreatitis. If pancreatitis is suspected,<br \/>\n      promptly discontinue JANUVIA and initiate appropriate management. It is<br \/>\n      unknown whether patients with a history of pancreatitis are at increased<br \/>\n      risk of developing pancreatitis while taking JANUVIA.\n    <\/p>\n<p>\n      Assessment of renal function is recommended prior to initiating JANUVIA<br \/>\n      and periodically thereafter. A dosage adjustment is recommended in<br \/>\n      patients with moderate or severe renal insufficiency and in patients<br \/>\n      with end-stage renal disease requiring hemodialysis or peritoneal<br \/>\n      dialysis. Caution should be used to ensure that the correct dose of<br \/>\n      JANUVIA is prescribed.\n    <\/p>\n<p>\n      There have been postmarketing reports of worsening renal function,<br \/>\n      including acute renal failure, sometimes requiring dialysis. A subset of<br \/>\n      these reports involved patients with renal insufficiency, some of whom<br \/>\n      were prescribed inappropriate doses of sitagliptin.\n    <\/p>\n<p>\n      When JANUVIA<sup><b> <\/b><\/sup>was used in combination with a<br \/>\n      sulfonylurea or insulin, medications known to cause hypoglycemia, the<br \/>\n      incidence of hypoglycemia was increased over that of placebo. Therefore,<br \/>\n      a lower dose of sulfonylurea or insulin may be required to reduce the<br \/>\n      risk of hypoglycemia.\n    <\/p>\n<p>\n      The incidences (and rates) of hypoglycemia based on all reports of<br \/>\n      symptomatic hypoglycemia were: 12.2 percent (0.59 episodes per<br \/>\n      patient-year) for JANUVIA 100 mg in combination with glimepiride (with<br \/>\n      or without metformin), 1.8 percent (0.24 episodes per patient-year) for<br \/>\n      placebo in combination with glimepiride (with or without metformin),<br \/>\n      15.5 percent (1.06 episodes per patient-year) for JANUVIA (sitagliptin)<br \/>\n      100 mg in combination with insulin (with or without metformin), and 7.8<br \/>\n      percent (0.51 episodes per patient-year) for placebo in combination with<br \/>\n      insulin (with or without metformin).\n    <\/p>\n<p>\n      There have been postmarketing reports of serious hypersensitivity<br \/>\n      reactions in patients treated with JANUVIA, such as anaphylaxis,<br \/>\n      angioedema and exfoliative skin conditions including Stevens-Johnson<br \/>\n      syndrome. Onset of these reactions occurred within the first 3 months<br \/>\n      after initiation of treatment with JANUVIA, with some reports occurring<br \/>\n      after the first dose. If a hypersensitivity reaction is suspected,<br \/>\n      discontinue JANUVIA, assess for other potential causes for the event,<br \/>\n      and institute alternative treatment for diabetes.\n    <\/p>\n<p>\n      Angioedema has also been reported with other dipeptidyl peptidase-4<br \/>\n      (DPP-4) inhibitors. Use caution in a patient with a history of<br \/>\n      angioedema with another DPP-4 inhibitor because it is unknown whether<br \/>\n      such patients will be predisposed to angioedema with JANUVIA.\n    <\/p>\n<p>\n      There have been no clinical studies establishing conclusive evidence of<br \/>\n      macrovascular risk reduction with JANUVIA or with any other antidiabetic<br \/>\n      drug.\n    <\/p>\n<p>\n      In clinical studies, the adverse reactions reported, regardless of<br \/>\n      investigator assessment of causality, in greater than or equal to 5<br \/>\n      percent of patients treated with JANUVIA as monotherapy and in<br \/>\n      combination therapy, and more commonly than in patients treated with<br \/>\n      placebo, were upper respiratory tract infection, nasopharyngitis and<br \/>\n      headache.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50944542&amp;newsitemid=20140917005586&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=a193394dec78ff4606f7ccd54e56aa02\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><span class=\"bwuline\"><br \/>\n      <\/span>and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50944542&amp;newsitemid=20140917005586&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=226d3067f449e41a7d2c5ef726c36390\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50944542&amp;newsitemid=20140917005586&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=a9cc27e0feca23124befaccb765697de\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50944542&amp;newsitemid=20140917005586&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=36c0ab037dfe911953519efceacef2a3\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to Diabetes<\/b>\n    <\/p>\n<p>\n      Through our research initiatives, on our own and in collaboration with<br \/>\n      others, Merck is strengthening its leadership in diabetes to deliver a<br \/>\n      broad portfolio of solutions to help improve the management of diabetes.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50944542&amp;newsitemid=20140917005586&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=5760fdc08f7e40912d526b5fa15add66\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for JANUVIA (sitagliptin) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_pi.pdf&amp;esheet=50944542&amp;newsitemid=20140917005586&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_pi.pdf&amp;index=6&amp;md5=bca7c3f31be301dbec5ed38c8c60fbb5\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/j\/januvia\/januvia_pi.pdf<\/b><\/a><b><br \/>\n      and Medication Guide for JANUVIA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_mg.pdf&amp;esheet=50944542&amp;newsitemid=20140917005586&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_mg.pdf&amp;index=7&amp;md5=65769fcbca6172c539f01c8ff2f64b45\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/j\/januvia\/januvia_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>JANUVIA<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of Merck<br \/>\n      Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.<\/b>\n    <\/p>\n<p>\n      <sup>1<\/sup> HbA1c is an estimate of a person&#8217;s average blood glucose<br \/>\n      over a two- to three-month period.\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140917005586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, +1 (267) 305-3558<br \/>Michael Close,        +1 (267) 305-1221 or +1 (310) 617-1067<br \/>or<br \/>Investors:<br \/>Justin        Holko, +1 (908) 423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Omarigliptin significantly reduced HbA1c levels compared to placebo Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck\u2019s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Merck\u2019s once-daily DPP-4 inhibitor JANUVIA\u00ae (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Merck presented these data on omarigliptin, which has been shown to produce sustained DPP-4 inhibition, at an oral session at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting. \u201cDespite advances in diabetes care in recent years, many people living with type 2 diabetes are not at recommended blood sugar goals,\u201d said Peter Stein, M.D., vice president, Clinical Research, Diabetes and Endocrinology, Merck<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744924","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Omarigliptin significantly reduced HbA1c levels compared to placebo Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck\u2019s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Merck\u2019s once-daily DPP-4 inhibitor JANUVIA\u00ae (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Merck presented these data on omarigliptin, which has been shown to produce sustained DPP-4 inhibition, at an oral session at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting. \u201cDespite advances in diabetes care in recent years, many people living with type 2 diabetes are not at recommended blood sugar goals,\u201d said Peter Stein, M.D., vice president, Clinical Research, Diabetes and Endocrinology, Merck\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140917005586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\\\/\",\"name\":\"Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140917005586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2014-09-17T08:31:00+00:00\",\"dateModified\":\"2023-03-22T04:04:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140917005586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140917005586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes - Merck.com","og_description":"Omarigliptin significantly reduced HbA1c levels compared to placebo Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck\u2019s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Merck\u2019s once-daily DPP-4 inhibitor JANUVIA\u00ae (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Merck presented these data on omarigliptin, which has been shown to produce sustained DPP-4 inhibition, at an oral session at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting. \u201cDespite advances in diabetes care in recent years, many people living with type 2 diabetes are not at recommended blood sugar goals,\u201d said Peter Stein, M.D., vice president, Clinical Research, Diabetes and Endocrinology, Merck","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:51+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140917005586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/","name":"Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140917005586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2014-09-17T08:31:00+00:00","dateModified":"2023-03-22T04:04:51+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140917005586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140917005586r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-investigational-once-weekly-dpp-4-inhibitor-for-type-2-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"39e2a8f2-7de0-4f19-8d18-a7fd0708eeb0","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Presents-First-Phase-3-Data-in-Japanese-Patients-for-Omarigliptin-an-Investigational-Once-Weekly-DPP-4-Inhibitor-for-Type-2-Dia-ZOPYB.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744924\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744924"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}